Noribogainalog (nor-IBG), also known as 9-hydroxyibogaminalog or as GATC-021, is a drug of the ibogalog family related to noribogaine. It is a simplified analogue of noribogaine.
Pharmacology Pharmacodynamics Noribogainalog acts as a potent serotonin 5-HT2A receptor partial agonist ( ≈ 90nM; = 35–45%). It is also a partial agonist of the serotonin 5-HT6 receptor ( = 29%), whereas it is not an agonist of the serotonin 5-HT2B and 5-HT7 receptors. The drug additionally has activity as a dopamine transporter (DAT) chaperone.
Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures. However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin. In addition, a subsequent study found that the highest assessed dose produced significant hypolocomotion and that the drug also reduced fentanyl self-administration.
Pharmacokinetics Noribogainalog shows relatively low expected blood–brain barrier permeability.
Chemistry Synthesis The chemical synthesis of noribogainalog has been described.
Analogues Analogues of noribogainalog include catharanthalog, ibogainalog, ibogaminalog, PNU-22394, tabernanthalog, 4-allyl-6-oxa-noribogainalog, and noribogaine, among others.
History Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.
See also Ibogalog
References
External links Noribogainalog - Isomer Design